Evidence map›Paper›PMID 40124187›Full record

ArticleUrology case reports2025

Molecular profiling of basal cell carcinoma of the prostate: A case report and literature review.

Luca Bertozzi, Eileen Zhang, Mohadese Behtaj, Olivia Gordon, Michael J Whalen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luca BertozziThe George Washington University School of Medicine and Health Sciences, 2300 I St NW, Washington, DC, 20052, USA.
Eileen ZhangUniversity of Maryland, 7901 Regents Drive, College Park, MD, 20742, USA.
Mohadese BehtajDepartment of Pathology, The George Washington Medical Faculty Associates, 2300 M Street NW, Suite 715, Washington, DC, 20037, USA.
Olivia GordonDepartment of Urology, The George Washington Medical Faculty Associates, 2150 Pennsylvania Ave NW, Suite 3-417, Washington, DC, 20037, USA.
Michael J WhalenDepartment of Urology, The George Washington Medical Faculty Associates, 2150 Pennsylvania Ave NW, Suite 3-417, Washington, DC, 20037, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate basal cell carcinoma (BCC) is a rare pathologic variant with a poorly understood molecular profile. Here, we describe a case of prostate BCC and compare its genetic alterations to cases in the literature. After presenting with hematuria, our patient underwent definitive radical prostatectomy for his localized biopsy-proven BCC. Somatic and germline testing revealed mutations in PIK3R1, KMT2D, and NOTCH1, and MUTYH, NBN, and MSH3, respectively. Upon literature review, we found that prostate BCC mutations disrupt cell growth, epigenetic regulation, and cell fate determination. With no consensus guidelines available, experimental targeted therapies have shown promise for prostate BCC management.

Indexed as

Basal cell carcinomaMolecular profilingProstate cancer

Identifiers

PMID40124187
PMCPMC11925511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.